Brightsurf Science News and Current Science News Events
 
Email a Friend Send to a friend
Printer Friendly Print Methotrexate treatment for rheumatoid arthritis effective the second time

Methotrexate treatment for rheumatoid arthritis effective the second time

February 24, 2006

A second course of methotrexate, the most commonly used drug to treat rheumatoid arthritis, is effective in nearly half of studied patients for whom a previous treatment with the drug was ineffective. These are the results of a study published today in Arthritis Research & Therapy, which also shows that a second treatment with methotrexate is particularly effective in patients who were given low dose methotrexate in their first treatment.

Theresa Kapral and colleagues from the Medical University of Vienna, Austria recruited patients with rheumatoid arthritis who had had at least two treatments with an anti-arthritis drug.




Kapral et al. identified 79 patients who had had a second methotrexate treatment lasting at least a year. The patients had terminated the first treatment either because it was ineffective or because of adverse events. Forty-two (53.2%) patients had an effective second treatment. The second treatment was effective in 23 (45.1%) of the patients who had stopped treatment because of inefficacy. Sixteen (66.7%) of the patients who had initially stopped treatment because of adverse events had a successful second treatment. The second treatment was more than twice as likely to be successful if the methotrexate dose in the first treatment had been low (lower or equal to 10mg per week) than if it had been high (greater than 17.5mg per week). There was no difference in efficacy between first and second treatment for other anti-arthritis drugs.

Physicians treating rheumatoid arthritis are in need of therapeutic options especially for patients with a history of repeated drug failures. The results of this study indicate that renewed institution of methotrexate might be one option that could be considered for the treatment of these patients.

BioMed Central



Related Methotrexate Treatment News Articles
Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients
New data presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment regimen, with positive results sustained up to one year later.

St. Jude gene study reveals basis of anticancer drug resistance in childhood leukemia
The first analysis of the genetic determinants of resistance to the anti-cancer drug methotrexate in childhood acute lymphoblastic leukemia (ALL) could offer a pathway to predicting such resistance and treatments to overcome it, according to a St. Jude Children's Research Hospital study.
More Methotrexate Treatment News Articles
Methotrexate not best option for psoriatic arthritis.(Musculoskeletal Disorders): An article from: Family Practice News
by Diana Mahoney

This digital document is an article from Family Practice News, published by Thomson Gale on December 1, 2007. The length of the article is 617 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...

Data may change treatment for juvenile dermatomyositis.(Clinical Rounds): An article from: Skin & Allergy News
by Gale Reference Team

This digital document is an article from Skin & Allergy News, published by Thomson Gale on July 1, 2007. The length of the article is 525 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Data may...

CellCept may control severe atopic dermatitis. (Beat Methotrexate, Azathioprine).: An article from: Skin & Allergy News
by Bruce Jancin

This digital document is an article from Skin & Allergy News, published by International Medical News Group on July 1, 2003. The length of the article is 659 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Methotrexate giant cell arteritis treatment trial (AARP Andrus Foundation final report)
by Mark J Kupersmith

MVAC Regimen, Cystectomy Add Life in Bladder Ca.(methotrexate, vinblastine, doxorubicin, and cisplatin for the treatment of metastatic bladder cancer): An article from: Internal Medicine News
by Timothy F. Kirn

This digital document is an article from Internal Medicine News, published by International Medical News Group on July 15, 2001. The length of the article is 328 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Rituximab/methotrexate promising in severe RA.(TNF-Blocker Alternative)(rheumatoid arthritis): An article from: Internal Medicine News
by Nancy Walsh

This digital document is an article from Internal Medicine News, published by International Medical News Group on March 15, 2004. The length of the article is 595 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Model: etanercept cost effective if MTX fails.(Dermatologic Therapy)(methotrexate): An article from: Skin & Allergy News
by Jeff Evans

This digital document is an article from Skin & Allergy News, published by International Medical News Group on June 1, 2004. The length of the article is 620 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

MRI useful for spotting erosive disease in RA.(At Least as Good as CT Imaging)(Magnetic resonance imaging)(rheumatoid arthritis): An article from: Internal Medicine News
by Steve Perlstein

This digital document is an article from Internal Medicine News, published by International Medical News Group on March 15, 2004. The length of the article is 431 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Calcipotriol reduced need for methotrexate in psoriasis Tx. (Study of 97 Patients).: An article from: Skin & Allergy News
by Michele G. Sullivan

This digital document is an article from Skin & Allergy News, published by International Medical News Group on June 1, 2003. The length of the article is 2492 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Early RA therapy gets a boost from doxycycline: ACR 50 response: adds minimal cost to methotrexate tx.(News)(rheumatoid arthritis)(American College of ... An article from: Internal Medicine News
by Nancy Walsh

This digital document is an article from Internal Medicine News, published by International Medical News Group on December 1, 2003. The length of the article is 703 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

© 2008 BrightSurf.com